Schizophrenia/Psychosis

Listen to discussion on results from a recent Phase 1b clinical trial.

Joining together to discuss psychosis, 3 British experts discuss various ways to respond to and help people who have experienced both trauma and psychosis.

New-onset symptoms of anxiety and depressive symptoms have erupted in the wake of the COVID-19 pandemic, yet even in the middle of the pandemic, there are reasons to be grateful.

A recent drug trial yields encouraging results.

COVID-19 has made treating patients who receive long-acting injectables complicated. The Chief Medical Officer of Houston Behavioral Healthcare Hospital offers suggestions on how best to proceed.

Recent research sheds light on the role of adjunctive long-acting injectable antipsychotics in treatment-resistant schizophrenia.

ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.

Manufacturing issues stall progress with ALKS 3831, Alkermes’s promising new drug for the treatment of schizophrenia and bipolar I disorder.

New research underlies the need for addressing identity in young patients during early stages of psychosis.

An explanation for the clinical presentation of delusions and hallucinations may have just been found.

More than 50% of patients with schizophrenia are estimated to be nonadherent with their antipsychotic medication regimen. What treatment solutions are available?

Antipsychotic medications for young children are not being prescribed appropriately, according to a recent study.

Data from a randomized phase III trial shows promise for new treatment strategy.

Researchers investigated in-hospital mortality and ICU admission in patients with COVID-19 with and without comorbid schizophrenia in a population-based cohort study.

A new, unique long-acting injectable for treating schizophrenia may be on the way.

When switching to this long-acting injectable antipsychotic, how long should an oral pre-switch antipsychotic be continued? Find out in this quiz.

This case illustrates the practical implications and effectiveness of the Minnesota Multiphasic Personality Inventory-2 in documenting patient recovery during treatment for delusional disorder.

Alkermes plc’s new drug, ALKS 3831, pending FDA approval, could be helpful in the treatment of patients with schizophrenia or bipolar I disorder.